S. Korea's Stem Cell Research Bounces Back From Decade-Old Scandal
This article was originally published in PharmAsia News
South Korea's regenerative-medicine research appears to have bounced back from a national scandal involving faked papers in 2005 to the point one of its research centers has more than 1,000 scientists working on the subject.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.